A Cancer That Hides in Plain Sight
Chronic lymphocytic leukemia, or CLL, is one of the most common blood cancers in adults. It affects a type of white blood cell called a B-lymphocyte, causing abnormal cells to build up in the blood, bone marrow, and lymph nodes. Most people are diagnosed after age 60.
Despite how common it is, CLL has always been difficult to visualize using standard imaging. The usual tool doctors use for cancer imaging — a PET scan using a tracer called 18F-FDG — often misses CLL because the disease doesn't "light up" well with that particular agent.
Why Standard Scans Fall Short
The standard PET scan tracer (18F-FDG) works by tracking how actively cells consume sugar. Cancer cells generally burn through sugar faster than normal cells, so they glow bright on the scan. But CLL cells are slow-growing and relatively quiet — they don't consume much sugar — so they often appear faint or invisible on a standard scan.
But here's what's different this time: researchers tested a newer tracer called 68Ga-pentixafor, which works through a completely different mechanism, and the difference in what it revealed was remarkable.
Instead of tracking sugar use, 68Ga-pentixafor latches onto a protein receptor called CXCR4 that sits on the surface of CLL cells. Think of CXCR4 like a docking port — and 68Ga-pentixafor as a ship that is designed to dock precisely there. Because CLL cells carry large numbers of this docking port, the tracer finds them far more easily than a sugar-based scan can.
Once the tracer binds to these cancer cells, they show up much more clearly on the PET scan image, making it possible to see exactly where the disease has spread.
A 60-year-old woman came to her doctors after six months of fever and swollen lymph nodes throughout her body. She underwent both the standard 18F-FDG PET scan and the newer 68Ga-pentixafor PET scan within two days of each other. Doctors then compared what each scan revealed, and confirmed the diagnosis through a tissue biopsy.
The newer 68Ga-pentixafor scan detected significantly more disease sites — including enlarged lymph nodes, activity in the spleen, and involvement of the bone marrow — all with much higher signal intensity than the standard scan. The standard FDG scan, by comparison, showed far less activity and missed several areas the newer scan caught clearly.
The biopsy confirmed the diagnosis of CLL, and the protein markers found matched perfectly with what both imaging methods suggested. The newer scan provided a far more complete picture of how widely the disease had spread through the body.
A single case report like this is a starting point, not a final answer.
That's Not the Whole Story
The real clinical value of better imaging in CLL goes beyond just seeing the disease — it affects treatment decisions. Knowing how extensively the cancer has spread helps doctors decide whether to treat immediately or monitor the disease, and which treatment approach to choose.
Fitting Into the Bigger Picture
Imaging in blood cancers has always lagged behind imaging in solid tumors. The medical community has been searching for tracers that work better in slow-growing, low-sugar-burning cancers like CLL. This case adds to a small but growing body of literature suggesting that CXCR4-targeting tracers like 68Ga-pentixafor may fill that gap — not just for CLL, but potentially for other blood cancers with similar biology.
If you have been diagnosed with CLL or are being evaluated for a blood cancer, 68Ga-pentixafor PET scanning is not yet a standard option at most medical centers. This tracer is used in some research and specialty settings, but it is not widely approved or available for routine CLL staging. Ask your oncologist or hematologist whether this type of imaging is being studied at your treatment center.
This report describes just one patient. A single case study cannot prove that the new scan is consistently better — it can only raise the possibility and motivate further research. The authors also reviewed existing published literature, which included other small studies, but large-scale clinical trials comparing the two tracers head-to-head in CLL have not yet been completed.
Researchers are now calling for prospective studies — carefully designed trials that follow larger groups of CLL patients and compare outcomes based on which imaging method was used. If those trials confirm that 68Ga-pentixafor PET consistently outperforms the standard scan, it could reshape how CLL is staged and monitored, potentially leading to better-matched treatments for patients.
